Software - Application
Compare Stocks
2 / 10Stock Comparison
DBD vs PAX
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
DBD vs PAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Software - Application | Asset Management |
| Market Cap | $2.75B | $1.92B |
| Revenue (TTM) | $3.86B | $384M |
| Net Income (TTM) | $110M | $86M |
| Gross Margin | 26.0% | 96.2% |
| Operating Margin | 8.0% | 34.2% |
| Forward P/E | 14.4x | 8.4x |
| Total Debt | $1.17B | $199M |
| Cash & Equiv. | $387M | $54M |
DBD vs PAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 23 | May 26 | Return |
|---|---|---|---|
| Diebold Nixdorf, In… (DBD) | 100 | 442.8 | +342.8% |
| Patria Investments … (PAX) | 100 | 83.5 | -16.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DBD vs PAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DBD is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.21
- 289.1% 10Y total return vs PAX's -19.3%
- +79.3% vs PAX's +14.9%
PAX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 2.6%, EPS growth 14.9%
- Lower volatility, beta 1.09, Low D/E 31.4%, current ratio 0.98x
- Beta 1.09, yield 5.0%, current ratio 0.98x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 2.6% NII/revenue growth vs DBD's 1.5% | |
| Value | Lower P/E (8.4x vs 14.4x) | |
| Quality / Margins | 22.3% margin vs DBD's 2.8% | |
| Stability / Safety | Beta 1.09 vs DBD's 1.21, lower leverage | |
| Dividends | 5.0% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +79.3% vs PAX's +14.9% | |
| Efficiency (ROA) | 6.3% ROA vs DBD's 2.9%, ROIC 12.5% vs 14.0% |
DBD vs PAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DBD vs PAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PAX leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
DBD is the larger business by revenue, generating $3.9B annually — 10.0x PAX's $384M. PAX is the more profitable business, keeping 22.3% of every revenue dollar as net income compared to DBD's 2.8%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3.9B | $384M |
| EBITDAEarnings before interest/tax | $400M | $174M |
| Net IncomeAfter-tax profit | $110M | $86M |
| Free Cash FlowCash after capex | $266M | $268M |
| Gross MarginGross profit ÷ Revenue | +26.0% | +96.2% |
| Operating MarginEBIT ÷ Revenue | +8.0% | +34.2% |
| Net MarginNet income ÷ Revenue | +2.8% | +22.3% |
| FCF MarginFCF ÷ Revenue | +6.9% | +67.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +163.6% | -40.5% |
Valuation Metrics
Evenly matched — DBD and PAX each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 22.3x trailing earnings, PAX trades at a 28% valuation discount to DBD's 31.1x P/E. On an enterprise value basis, DBD's 7.6x EV/EBITDA is more attractive than PAX's 15.7x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.7B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | 31.05x | 22.30x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.37x | 8.42x |
| PEG RatioP/E ÷ EPS growth rate | — | 7.92x |
| EV / EBITDAEnterprise value multiple | 7.64x | 15.74x |
| Price / SalesMarket cap ÷ Revenue | 0.72x | 5.01x |
| Price / BookPrice ÷ Book value/share | 2.66x | 3.00x |
| Price / FCFMarket cap ÷ FCF | 10.43x | 7.44x |
Profitability & Efficiency
PAX leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
PAX delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $10 for DBD. PAX carries lower financial leverage with a 0.31x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBD's 1.06x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +10.1% | +14.4% |
| ROA (TTM)Return on assets | +2.9% | +6.3% |
| ROICReturn on invested capital | +14.0% | +12.5% |
| ROCEReturn on capital employed | +14.1% | +13.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.06x | 0.31x |
| Net DebtTotal debt minus cash | $787M | $145M |
| Cash & Equiv.Liquid assets | $387M | $54M |
| Total DebtShort + long-term debt | $1.2B | $199M |
| Interest CoverageEBIT ÷ Interest expense | 6.68x | 7.45x |
Total Returns (Dividends Reinvested)
DBD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBD five years ago would be worth $38,342 today (with dividends reinvested), compared to $10,537 for PAX. Over the past 12 months, DBD leads with a +79.3% total return vs PAX's +14.9%. The 3-year compound annual growth rate (CAGR) favors DBD at 56.5% vs PAX's -0.5% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +23.3% | -23.4% |
| 1-Year ReturnPast 12 months | +79.3% | +14.9% |
| 3-Year ReturnCumulative with dividends | +283.4% | -1.4% |
| 5-Year ReturnCumulative with dividends | +283.4% | +5.4% |
| 10-Year ReturnCumulative with dividends | +289.1% | -19.3% |
| CAGR (3Y)Annualised 3-year return | +56.5% | -0.5% |
Risk & Volatility
Evenly matched — DBD and PAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
PAX is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than DBD's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBD currently trades 88.6% from its 52-week high vs PAX's 67.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.09x |
| 52-Week HighHighest price in past year | $89.05 | $17.80 |
| 52-Week LowLowest price in past year | $43.61 | $10.86 |
| % of 52W HighCurrent price vs 52-week peak | +88.6% | +67.6% |
| RSI (14)Momentum oscillator 0–100 | 47.4 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 460K | 885K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DBD as "Buy" and PAX as "Buy". Consensus price targets imply 49.5% upside for PAX (target: $18) vs 26.8% for DBD (target: $100). PAX is the only dividend payer here at 5.00% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $100.00 | $18.00 |
| # AnalystsCovering analysts | 13 | 5 |
| Dividend YieldAnnual dividend ÷ price | — | +5.0% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $0.60 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.8% | +2.9% |
PAX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBD leads in 1 (Total Returns). 2 tied.
DBD vs PAX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is DBD or PAX a better buy right now?
For growth investors, Patria Investments Limited (PAX) is the stronger pick with 2.
6% revenue growth year-over-year, versus 1. 5% for Diebold Nixdorf, Incorporated (DBD). Patria Investments Limited (PAX) offers the better valuation at 22. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate Diebold Nixdorf, Incorporated (DBD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DBD or PAX?
On trailing P/E, Patria Investments Limited (PAX) is the cheapest at 22.
3x versus Diebold Nixdorf, Incorporated at 31. 1x. On forward P/E, Patria Investments Limited is actually cheaper at 8. 4x.
03Which is the better long-term investment — DBD or PAX?
Over the past 5 years, Diebold Nixdorf, Incorporated (DBD) delivered a total return of +283.
4%, compared to +5. 4% for Patria Investments Limited (PAX). Over 10 years, the gap is even starker: DBD returned +289. 1% versus PAX's -19. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DBD or PAX?
By beta (market sensitivity over 5 years), Patria Investments Limited (PAX) is the lower-risk stock at 1.
09β versus Diebold Nixdorf, Incorporated's 1. 21β — meaning DBD is approximately 11% more volatile than PAX relative to the S&P 500. On balance sheet safety, Patria Investments Limited (PAX) carries a lower debt/equity ratio of 31% versus 106% for Diebold Nixdorf, Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — DBD or PAX?
By revenue growth (latest reported year), Patria Investments Limited (PAX) is pulling ahead at 2.
6% versus 1. 5% for Diebold Nixdorf, Incorporated (DBD). On earnings-per-share growth, the picture is similar: Diebold Nixdorf, Incorporated grew EPS 677. 3% year-over-year, compared to 14. 9% for Patria Investments Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DBD or PAX?
Patria Investments Limited (PAX) is the more profitable company, earning 22.
3% net margin versus 2. 5% for Diebold Nixdorf, Incorporated — meaning it keeps 22. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAX leads at 34. 2% versus 8. 8% for DBD. At the gross margin level — before operating expenses — PAX leads at 96. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DBD or PAX more undervalued right now?
On forward earnings alone, Patria Investments Limited (PAX) trades at 8.
4x forward P/E versus 14. 4x for Diebold Nixdorf, Incorporated — 6. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PAX: 49. 5% to $18. 00.
08Which pays a better dividend — DBD or PAX?
In this comparison, PAX (5.
0% yield) pays a dividend. DBD does not pay a meaningful dividend and should not be held primarily for income.
09Is DBD or PAX better for a retirement portfolio?
For long-horizon retirement investors, Patria Investments Limited (PAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
09), 5. 0% yield). Both have compounded well over 10 years (PAX: -19. 3%, DBD: +289. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DBD and PAX?
These companies operate in different sectors (DBD (Technology) and PAX (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DBD is a small-cap quality compounder stock; PAX is a small-cap income-oriented stock. PAX pays a dividend while DBD does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.